News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Study Shows Teva Pharmaceutical Industries Limited’s Laquinimod Slows MS
June 20, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, June 20 (Reuters) - Teva Pharmaceutical Industries' multiple sclerosis pill laquinimod appears to slow the disease and is well-tolerated by people with the relapsing form of the incurable condition, researchers said on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
MORE ON THIS TOPIC
IN PARTNERSHIP WITH DIA
Economic Challenges, Strategic Investments: Reshaping the Women’s Health Landscape
April 24, 2025
·
1 min read
·
Lori Ellis
Lung cancer
Summit’s Bispecific Beats Yet Another Cancer Med, Pressuring Keytruda’s ‘Supremacy’
April 23, 2025
·
2 min read
·
Tristan Manalac
Neuropsychiatric disorders
‘Strike 2?’ BMS Stumbles Again as Cobenfy Disappoints in Schizophrenia
April 23, 2025
·
2 min read
·
Tristan Manalac
Breast cancer
Gilead’s Trodelvy, With Keytruda, Slows Disease Progression in Triple-Negative Breast Cancer
April 22, 2025
·
2 min read
·
Tristan Manalac